Protocolized hemostatic factor use in major thoracic aortic surgery

J Cardiovasc Surg (Torino). 2019 Oct;60(5):633-636. doi: 10.23736/S0021-9509.19.10819-1. Epub 2019 Jul 12.

Authors

Matthew A Wagner¹, Hanghang Wang¹, Ehsan Benrashid¹, Jeffrey E Keenan¹, Yamini Krishnamurthy², Jerrold H Levy², Ian J Welsby², G Chad Hughes³

Affiliations

¹ Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical, Center, Durham, NC, USA.
² Cardiothoracic Division, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
³ Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical, Center, Durham, NC, USA - gchad.hughes@duke.edu.

PMID: 31302952
DOI: 10.23736/S0021-9509.19.10819-1

No abstract available

Publication types

Letter

MeSH terms

Aged
Aorta, Thoracic / surgery*
Blood Coagulation Disorders / drug therapy
Cardiovascular Surgical Procedures
Dose-Response Relationship, Drug
Factor VIIa / administration & dosage*
Factor VIIa / adverse effects
Female
Hemostatics / administration & dosage*
Hemostatics / adverse effects
Humans
Male
Middle Aged
Postoperative Hemorrhage / drug therapy*
Recombinant Proteins / administration & dosage
Recombinant Proteins / adverse effects
Retrospective Studies
Thromboembolism / chemically induced

Substances

Hemostatics
Recombinant Proteins
recombinant FVIIa
Factor VIIa